Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Fibrinogen concentrate is not a shortcut.
It’s a deliberate clinical choice.
In acute bleeding, fibrinogen concentrate is often discussed in terms of speed and convenience. But its real value is not how fast it can be given – it’s when and why it is given. It’s when fibrinogen deficiency is addressed, and why supporting clot stability early matters.
Fibrinogen concentrate provides a known, standardized dose, without the volume burden or preparation time associated with cryoprecipitate. In critical bleeding, knowing what to expect makes the decision safer.
It’s not that fibrinogen’s role in coagulation is unknown; the difference lies in how early it is addressed, before bleeding escalates into loss of control.
When used appropriately, it allows teams to:
- correct hypofibrinogenemia promptly
- avoid unnecessary volume overload
- and target the hemostatic deficit more precisely
From a blood bank perspective, fibrinogen concentrate represents a shift in thinking: from reactive transfusion
to intentional hemostatic management.
From a blood bank perspective, fibrinogen concentrate also offers operational clarity. It reduces pressure on cryoprecipitate stock, which is often limited, variable in availability, and time sensitive once thawed. Its longer shelf life allows for better inventory stability, without compromising readiness for true bleeding emergencies.
It requires clear protocols, shared clinical understanding, and respect for timing.
- Used thoughtfully, it strengthens care.
- Used casually, it becomes just another product.
In bleeding patients, precision is not a luxury – it is part of patient safety.Its value lies in judgment, not availability.”
Other posts featuring Tagreed Alkaltham on Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS